688513 Chengdu Easton Biopharmaceuticals
- 54.00
- -1.65-2.96%
Chengdu Easton Biopharmaceuticals News
Chengdu Easton Biopharmaceuticals (688513.SH): has repurchased 0.9086% of the company's shares.
Chengdu Easton Biopharmaceuticals (688513.SH) announced on June 3 that as of the end of May 2024, the company had repurchased a total of 1,091,092 shares of the company through centralized bidding trading, accounting for 0.9086% of the total share capital. The highest purchase price was 56.05 yuan/share, the lowest purchase price was 43.5 yuan/share, and the total transaction amount was RMB 54,282,923.09 (excluding stamp duty, transaction fees, and other trading expenses).
Yuandong Biotech (688513.SH) grants 728,000 restricted shares
Yuandong Biotech (688513.SH) issued an announcement. The company's board of directors determined the 2024 restricted stock incentive plan...
China Gives Green Light for Easton Biopharma's Arterial Occlusive Disease Tablets
China's medical products administrator granted Chengdu Easton Biopharmaceuticals (SHA:688513) a drug registration certificate for its beraprost sodium tablets indicated for ulcers and other symptoms c
Yuandong Biology (688513.SH): Beprost sodium tablets obtained drug registration certificate
Gelonghui, May 21丨Yuandong Biology (688513.SH) announced that the company recently received the “Drug Registration Certificate” approved and issued by the State Drug Administration. The main component of beprost sodium tablets is beprost sodium. The indication is to improve symptoms such as ulcers, intermittent claudication, pain, and cold sensation caused by chronic arterial occlusive disease.
Yuandong Biotech (688513.SH): 0.9086% of shares have been repurchased
Gelonghui, May 6, 丨 Yuandong Biotech (688513.SH) announced that by the end of April 2024, the company had repurchased a total of 1,092 shares of the company through centralized bidding transactions, accounting for 0.9086% of the company's total share capital. The highest purchase price was 56.05 yuan/share, the lowest price was 43.5 yuan/share, and the total transaction amount was RMB 54,282,923.09 (excluding transaction fees such as stamp duty and transaction fees).
Yuandong Biotech (688513.SH): Phase III clinical trial of eugliptin tablets as a single agent to treat type 2 diabetes reached the expected goals
Gelonghui, April 30丨Yuandong Biology (688513.SH) announced that the phase III clinical trial of the self-developed Class 1 new drug eugliptin tablets to treat type 2 diabetes as a single agent has recently obtained a clinical trial summary report and achieved the expected goals. Phase III clinical trial results showed that euglithin tablets can significantly improve glycated hemoglobin (HbA1c), fasting blood sugar, and blood sugar 2 hours after meals in patients with type 2 diabetes who have poor exercise control on a simple diet. Euglitine tablets as a single drug treatment for Chinese type 2 diabetics with poor exercise control on a simple diet can significantly improve patients' glycated hemoglobin, fasting blood sugar, and after meals2
Yuandong Biotech (688513.SH) plans to launch 2024 employee stock ownership plan
According to Zhitong Finance App News, Yuandong Biotech (688513.SH) disclosed the 2024 employee shareholding plan (draft), with no more than 208 participants. The total number of participants to be raised is no more than 346.938 million yuan. Using “shares” as the subscription unit, each share is 1 yuan. The maximum number of shares of the employee shareholding plan is 346.938 million shares. The final total amount of capital raised is based on the actual total amount of capital raised. The source of shares in the employee stock ownership plan is Yuandong Biotech's A-share common stock shares in the company's repurchase special securities account. After the employee shareholding plan is reviewed and approved by the company's shareholders' meeting, laws and regulations such as non-transactional transfers will be passed
Chengdu Easton Biopharmaceuticals Co., Ltd. (SHSE:688513) Adds CN¥461m in Market Cap and Insiders Have a 49% Stake in That Gain
Key Insights Significant insider control over Chengdu Easton Biopharmaceuticals implies vested interests in company growth The top 3 shareholders own 50% of the company Using data from analyst for
Yuandong Biotech (688513.SH) announced its 2023 annual results, with net profit of 227 million yuan, a year-on-year decrease of 8.09%
Yuandong Biotech (688513.SH) disclosed its 2023 annual report, and the company achieved revenue of 11 in 2023...
Easton Biopharma's Unit Gets Nod to Market Bisoprolol Amlodipine Tablets
Chengdu Easton Biopharmaceuticals' (SHA:688513) unit, Chengdu Shuode Pharmaceutical, obtained a drug registration certificate from China's National Medical Products Administration for its bisoprolol a
Yuandong Biology (688513.SH): Butorphinol tartrate injection obtained drug registration certificate
Zhitong Finance App News, Yuandong Biotech (688513.SH) issued an announcement. The company recently received the “Drug Registration Certificate” approved and issued by the State Drug Administration (hereinafter referred to as the “State Drug Administration”), involving the drug: “butorphinol tartrate injection”. The main component of butorphinol tartrate injection is butorphinol tartrate, which is a Class II psychotropic drug stipulated in the National Regulations on the Administration of Narcotic Drugs and Psychotropic Substances. The indications are for treating various types of cancer pain and pain after surgery. According to the announcement, the company's butorphinol tartrate injections were declared according to the 3 types of chemicals, and after approval, they were deemed to have passed 1
Yuandong Biotech (688513.SH): A total of 0.9086% of the company's shares have been purchased at a cost of 54.282,900 yuan
Gelonghui, April 2, 丨 Yuandong Biotech (688513.SH) announced that by the end of March 2024, the company had repurchased a total of 1.0911 million shares through centralized bidding transactions, accounting for 0.9086% of the company's total share capital. The highest purchase price was 56.05 yuan/share, the lowest price was 43.5 yuan/share, and the total transaction amount was RMB 54.2829 million (excluding transaction fees such as stamp duty and transaction fees).
Yuandong Biotech (688513.SH): Preliminary determination that the inquiry transfer price was 51.5 yuan/share. The transferees were 7 institutional investors
Yuandong Biotech (688513.SH) disclosed shareholders' inquiries and transfer pricing. After inquiring with institutional investors, preliminary...
Yuandong Biotech (688513.SH): Shareholders plan to transfer 2.7% of shares in an inquiry
Gelonghui, March 29丨Yuandong Biotech (688513.SH) announced that it intends to participate in Yuandong Biotech's initial shareholder inquiry and transfer. The shareholders are Chengdu Nanyuan Investment Partnership (limited partnership), Chengdu Zhuyuan Investment Partnership (limited partnership), and Chengdu Juyuan Investment Partnership (limited partnership); the total number of shares to be transferred by the seller is 3,240,000 shares, accounting for 2.70% of Yuandong Biotech's total share capital; this inquiry transfer is an undisclosed transfer and will not be carried out through centralized bidding. The transferee transfers the transferred shares through an inquiry, and cannot be transferred within 6 months after the transfer.
Yuandong Biology (688513.SH): Received a government subsidy of 35.5084 million yuan related to revenue
Gelonghui March 22丨Yuandong Biology (688513.SH) announced that the company and its wholly-owned subsidiaries Tibet Runhe Pharmaceutical Co., Ltd., Sichuan Sunshine Runhe Pharmaceutical Co., Ltd., Chengdu Shuode Pharmaceutical Co., Ltd., Sichuan Aoki Pharmaceutical Co., Ltd., and Chengdu Yuluo Biotechnology Co., Ltd. have received a total of RMB 35.5084 million in government grants related to revenue from July 22, 2023 to March 21, 2024.
Is Chengdu Easton Biopharmaceuticals (SHSE:688513) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Yuandong Biotech (688513.SH): A total cost of 54.28 million yuan to buy back 0.9% of the shares
Gelonghui, March 1, 丨 Yuandong Biotech (688513.SH) announced that by the end of February 2024, Chengdu Yuandong Biopharmaceutical Co., Ltd. had repurchased a total of 1,092 shares of the company through centralized bidding transactions, accounting for 0.9086% of the company's total share capital. The highest purchase price was 56.05 yuan/share, the lowest price was 43.5 yuan/share, and the total transaction amount was RMB 54,282,923.09.
Yuandong Biology (688513.SH): Two core technicians resigned and added the recognition of Qiao Zhitao as a core technician
Zhitong Finance App News, Yuan Dong Biotech (688513.SH) issued an announcement. TIAN RONGLIN, the company's deputy general manager and core technician, applied for resignation due to personal reasons, and the core technician Xiang Yongzhe resigned due to personal reasons. After resigning, he no longer held any position in the company. The company newly identified Qiao Zhitao as the company's core technical staff, and he took over the work Xiang Yongzhe was responsible for.
Yuandong Biotech (688513.SH): Net profit in 2023 fell 8.21% year on year
Gelonghui, Feb. 23, 丨 Yuandong Biotech (688513.SH) announced the 2023 annual performance report. The company achieved total operating income of 1116.3342 million yuan in 2023, a year-on-year decrease of 4.60%; realized net profit attributable to owners of the parent company was 226.2886 million yuan, a year-on-year decrease of 8.21%; realized net profit attributable to owners of the parent company after deducting non-recurring profit and loss of 157.4571 million yuan, a year-on-year decrease of 4.40%; at the end of 2023, the company's total assets were 334,168,900 yuan, up from the beginning of the period. 10.74%, owned by parent company
Some Shareholders Feeling Restless Over Chengdu Easton Biopharmaceuticals Co., Ltd.'s (SHSE:688513) P/E Ratio
There wouldn't be many who think Chengdu Easton Biopharmaceuticals Co., Ltd.'s (SHSE:688513) price-to-earnings (or "P/E") ratio of 22.4x is worth a mention when the median P/E in China is similar at a
Analysis
Price Target
No Data
